The mechanistic links between proteasome activity, aging and agerelated diseases

Current Genomics

Volumn 15, Issue 1, 2014, Pages 38-51

  Saez, Isabel ^a   Vilchez, David ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Aging; Alzheimer's disease; Huntington's disease; Parkinson's disease; Proteasome; Proteostasis; Stem cells

Indexed keywords

ALPHA SYNUCLEIN; EPIDERMAL GROWTH FACTOR; HEAT SHOCK PROTEIN 90; PROTEASOME; UBIQUITIN;

AGING; APOPTOSIS; AUTOPHAGY; MULTIPLE MYELOMA; PHENOTYPE; PREVALENCE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; REVIEW; RISK FACTOR; SENESCENCE; STRESS; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

EID: 84896344634     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920291501140306113344     Document Type: Review

References (243)

1. Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. Adapting proteostasis for disease intervention. Science, 2008, 319(5865), 916-9.
2. Powers, E.T.; Morimoto, R.I.; Dillin, A.; Kelly, J.W.; Balch, W.E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem., 2009, 78, 959-91.
3. Taylor, R.C.; Dillin, A. Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol., 2011,3(5). doi: 10.1101/cshperspect.a004440
4. Morimoto, R.I. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev., 2008, 22(11), 1427-38.
5. Morimoto, R.I.; Cuervo, A.M. Protein homeostasis and aging: taking care of proteins from the cradle to the grave. J. Gerontol. A Biol. Sci. Med. Sci., 2009, 64(2), 167-70.
6. Vabulas, R. M.; Raychaudhuri, S.; Hayer-Hartl, M.; Hartl, F. U. Protein folding in the cytoplasm and the heat shock response. Cold Spring Harb. Perspect. Biol., 2010, 2(12), a004390.
7. Lopez-Otin, C.; Blasco, M. A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell, 2013, 153(6), 1194-217.
8. Selkoe, D. J. Alzheimer's disease. Cold Spring Harb. Perspect. Biol., 2011, 3(7).
9. Bosco, D. A.; LaVoie, M. J.; Petsko, G. A.; Ringe, D. Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. Cold Spring Harb. Perspect. Biol., 2011, 3(10), a007500.
10. Finkbeiner, S. Huntington's Disease. Cold Spring Harb. Perspect. Biol., 2011,3(6).
11. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem., 2009, 78, 477-513.
12. Rubinsztein, D. C.; Marino, G.; Kroemer, G. Autophagy and aging. Cell, 2011, 146(5), 682-95.
13. Tanaka, K.; Matsuda, N. Proteostasis and neurodegeneration: The roles of proteasomal degradation and autophagy. Biochim. Biophys. Acta, 2013, 1843(1), 197-204.
14. Wong, E.; Cuervo, A. M. Integration of clearance mechanisms: the proteasome and autophagy. Cold Spring Harb. Perspect. Biol., 2010, 2(12), a006734.
15. Huang, Q.; Figueiredo-Pereira, M. E. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis, 2010, 15(11), 1292-311.
16. Schmidt, M.; Finley, D. Regulation of proteasome activity in health and disease. Biochim. Biophys. Acta, 2013, 1843(1), 13-25.
17. Vilchez, D.; Morantte, I.; Liu, Z.; Douglas, P. M.; Merkwirth, C.; Rodrigues, A. P.; Manning, G.; Dillin, A. RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature, 2012, 489(7415), 263-268.
18. Hansen, M.; Chandra, A.; Mitic, L. L.; Onken, B.; Driscoll, M.; Kenyon, C. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet., 2008, 4(2), e24.
19. Hars, E. S.; Qi, H.; Ryazanov, A. G.; Jin, S.; Cai, L.; Hu, C.; Liu, L. F. Autophagy regulates ageing in C. elegans. Autophagy, 2007, 3(2), 93-5.
20. Lapierre, L. R.; Hansen, M. Lessons from C. elegans: signaling pathways for longevity. Trends Endocrinol. Metab., 2012, 23(12), 637-44.
21. Lapierre, L. R.; Melendez, A.; Hansen, M. Autophagy links lipid metabolism to longevity in C. elegans. Autophagy, 2012, 8(1), 144-6.
22. Melendez, A.; Talloczy, Z.; Seaman, M.; Eskelinen, E. L.; Hall, D. H.; Levine, B. Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science, 2003, 301(5638), 1387-91.
23. Cohen, E.; Bieschke, J.; Perciavalle, R. M.; Kelly, J. W.; Dillin, A. Opposing activities protect against age-onset proteotoxicity. Science, 2006, 313(5793), 1604-10.
24. Cohen, E.; Paulsson, J. F.; Blinder, P.; Burstyn-Cohen, T.; Du, D.; Estepa, G.; Adame, A.; Pham, H. M.; Holzenberger, M.; Kelly, J. W.; Masliah, E.; Dillin, A. Reduced IGF-1 signaling delays ageassociated proteotoxicity in mice. Cell, 2009, 139(6), 1157-69.
25. Buckley, S. M.; Aranda-Orgilles, B.; Strikoudis, A.; Apostolou, E.; Loizou, E.; Moran-Crusio, K.; Farnsworth, C. L.; Koller, A. A.; Dasgupta, R.; Silva, J. C.; Stadtfeld, M.; Hochedlinger, K.; Chen, E. I.; Aifantis, I. Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell, 2012, 11(6), 783-98.
26. Okita, Y.; Nakayama, K. I. UPS delivers pluripotency. Cell Stem Cell, 2012, 11(6), 728-30.
27. Tanaka, K. The proteasome: from basic mechanisms to emerging roles. Keio J. Med., 2013, 62(1), 1-12.
28. Vilchez, D.; Boyer, L.; Morantte, I.; Lutz, M.; Merkwirth, C.; Joyce, D.; Spencer, B.; Page, L.; Masliah, E.; Berggren, T. W.; Gage, F. H.; Dillin, A. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature, 2012, 489(7415), 304-308.
29. Ciehanover, A.; Hod, Y.; Hershko, A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem. Biophys. Res. Commun., 1978, 81(4), 1100-5.
30. Hershko, A.; Ciechanover, A.; Heller, H.; Haas, A. L.; Rose, I. A. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc. Natl. Acad. Sci. USA, 1980, 77(4), 1783-6.
31. Wilkinson, K. D.; Urban, M. K.; Haas, A. L. Ubiquitin is the ATPdependent proteolysis factor I of rabbit reticulocytes. J. Biol. Chem., 1980, 255(16), 7529-32.
32. Ciechanover, A.; Elias, S.; Heller, H.; Hershko, A. "Covalent affinity" purification of ubiquitin-activating enzyme. J. Biol. Chem., 1982, 257(5), 2537-42.
33. Hershko, A.; Heller, H.; Elias, S.; Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem., 1983, 258(13), 8206-14.
34. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem., 2001, 70, 503-33.
35. Iwai, K. iverse ubiquitin signaling in NF-kappaB activation. Trends Cell. Biol., 2012, 22(7), 355-64.
36. Thrower, J. S.; Hoffman, L.; Rechsteiner, M.; Pickart, C. M. Recognition of the polyubiquitin proteolytic signal. EMBO J., 2000, 19(1), 94-102.
37. Ikeda, F.; Dikic, I. Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep., 2008, 9(6), 536-42.
38. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. tructure of 20S proteasome from yeast at 2.4 A resolution. Nature, 1997, 386(6624), 463-71.
39. Orlowski, M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry,1990, 29(45), 10289-97.
40. Orlowski, M.; Cardozo, C.; Michaud, C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry, 1993, 32(6), 1563-72.
41. Gaczynska, M.; Rock, K.L.; Goldberg, A.L. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature, 1993, 365(6443), 264-7.
42. Monaco, J.J.; McDevitt, H.O. H-2-linked low-molecular weight polypeptide antigens assemble into an unusual macromolecular complex. Nature, 1984, 309(5971), 797-9.
43. Kisselev, A.F.; Goldberg, A.L. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol., 2005, 398, 364-78.
44. Baugh, J.M.; Viktorova, E.G.; Pilipenko, E.V. Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination. J. Mol. Biol., 2009, 386(3), 814-27.
45. Hoffman, L.; Pratt, G.; Rechsteiner, M. Multiple forms of the 20 S multicatalytic and the 26 S ubiquitin/ATP-dependent proteases from rabbit reticulocyte lysate. J. Biol. Chem., 1992, 267(31), 22362-8.
46. Hough, R.; Pratt, G.; Rechsteiner, M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J. Biol. Chem., 1987, 262(17), 8303-13.
47. Waxman, L.; Fagan, J.M.; Goldberg, A.L. Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates. J. Biol. Chem., 1987, 262(6), 2451-7.
48. Deveraux, Q.; Ustrell, V.; Pickart, C.; Rechsteiner, M. A 26 S protease subunit that binds ubiquitin conjugates. J. Biol. Chem., 1994, 269(10), 7059-61.
49. Beyer, A. Sequence analysis of the AAA protein family. Protein Sci., 1997, 6(10), 2043-58.
50. Udvardy, A. Purification and characterization of a multiprotein component of the Drosophila 26 S (1500 kDa) proteolytic complex. J. Biol. Chem., 1993, 268(12), 9055-62.
51. Ma, C.P.; Slaughter, C.A.; DeMartino, G.N. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem., 1992, 267(15), 10515-23.
52. Ahn, K.; Erlander, M.; Leturcq, D.; Peterson, P.A.; Fruh, K.; Yang, Y. In vivo characterization of the proteasome regulator PA28. J. Biol. Chem., 1996, 271(30), 18237-42.
53. Demartino, G.N.; Gillette, T.G. Proteasomes: machines for all reasons. Cell, 2007, 129(4), 659-62.
54. Forster, A.; Masters, E. I.; Whitby, F. G.; Robinson, H.; Hill, C. P. The 1.9 A structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. Mol. Cell., 2005, 18(5), 589-99.
55. Dubiel, W.; Pratt, G.; Ferrell, K.; Rechsteiner, M. Purification of an 11 S regulator of the multicatalytic protease. J. Biol. Chem., 1992, 267(31), 22369-77.
56. Realini, C.; Jensen, C. C.; Zhang, Z.; Johnston, S. C.; Knowlton, J. R.; Hill, C. P.; Rechsteiner, M. Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. J. Biol. Chem., 1997, 272(41), 25483-92.
57. Sijts, A.; Sun, Y.; Janek, K.; Kral, S.; Paschen, A.; Schadendorf, D.; Kloetzel, P. M. The role of the proteasome activator PA28 in MHC class I antigen processing. Mol. Immunol., 2002, 39(3-4), 165-9.
58. Li, X.; Amazit, L.; Long, W.; Lonard, D.M.; Monaco, J.J.; O'Malley, B. W. Ubiquitin-and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell., 2007, 26(6), 831-42.
59. Ustrell, V.; Hoffman, L.; Pratt, G.; Rechsteiner, M. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J., 2002, 21(13), 3516-25.
60. Blickwedehl, J.; Agarwal, M.; Seong, C.; Pandita, R. K.; Melendy, T.; Sung, P.; Pandita, T. K.; Bangia, N. Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability. Proc. Natl. Acad. Sci. USA, 2008, 105(42), 16165-70.
61. Schmidt, M.; Haas, W.; Crosas, B.; Santamaria, P. G.; Gygi, S. P.; Walz, T.; Finley, D. The HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core particle. Nat. Struct. Mol. Biol., 2005, 12(4), 294-303.
62. Hartl, F. U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature, 2011, 475(7356), 324-32.
63. Gidalevitz, T.; Prahlad, V.; Morimoto, R. I. The stress of protein misfolding: from single cells to multicellular organisms. Cold Spring Harb. Perspect. Biol., 2011, 3(6). doi: 10.1101/cshperspect. a009704
64. Calderwood, S. K.; Murshid, A.; Prince, T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging--a mini-review. Gerontology, 2009, 55(5), 550-8.
65. Hsu, A. L.; Murphy, C. T.; Kenyon, C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science, 2003, 300(5622), 1142-5.
66. Morley, J. F.; Morimoto, R. I. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol. Biol. Cell, 2004, 15(2), 657-64.
67. Morrow, G.; Samson, M.; Michaud, S.; Tanguay, R. M. verexpression of the small mitochondrial Hsp22 extends Drosophila life span and increases resistance to oxidative stress. FASEB J., 2004, 18(3), 598-9.
68. Walker, G. A.; Lithgow, G. J. Lifespan extension in C. elegans by a molecular chaperone dependent upon insulin-like signals. Aging Cell, 2003, 2(2), 131-9.
69. Min, J. N.; Whaley, R. A.; Sharpless, N. E.; Lockyer, P.; Portbury, A. L.; Patterson, C. CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol. Cell Biol., 2008, 28(12), 4018-25.
70. Swindell, W.R.; Masternak, M.M.; Kopchick, J.J.; Conover, C.A.; Bartke, A.; Miller, R.A. Endocrine regulation of heat shock protein mRNA levels in long-lived dwarf mice. Mech. Ageing Dev., 2009, 130(6), 393-400.
71. Cuervo, A.M.; Dice, J.F. Age-related decline in chaperonemediated autophagy. J. Biol. Chem., 2000, 275(40), 31505-13.
72. Shibata, M.; Lu, T.; Furuya, T.; Degterev, A.; Mizushima, N.; Yoshimori, T.; MacDonald, M.; Yankner, B.; Yuan, J. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J. Biol. Chem., 2006, 281(20), 14474-85.
73. Zhang, C.; Cuervo, A.M. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat. Med., 2008, 14(9), 959-65.
74. Blagosklonny, M. V. Rapamycin-induced glucose intolerance: hunger or starvation diabetes. Cell Cycle, 2011, 10(24), 4217-24.
75. Harrison, D.E.; Strong, R.; Sharp, Z.D.; Nelson, J.F.; Astle, C.M.; Flurkey, K.; Nadon, N.L.; Wilkinson, J.E.; Frenkel, K.; Carter, C.S.; Pahor, M.; Javors, M.A.; Fernandez, E.; Miller, R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009, 460(7253), 392-5.
76. Wilkinson, J.E.; Burmeister, L.; Brooks, S.V.; Chan, C.C.; Friedline, S.; Harrison, D.E.; Hejtmancik, J.F.; Nadon, N.; Strong, R.; Wood, L.K.; Woodward, M.A.; Miller, R.A. Rapamycin slows aging in mice. Aging Cell, 2012, 11(4), 675-82.
77. Simonsen, A.; Cumming, R.C.; Finley, K.D. Linking lysosomal trafficking defects with changes in aging and stress response in Drosophila. Autophagy, 2007, 3(5), 499-501.
78. Bjedov, I.; Toivonen, J.M.; Kerr, F.; Slack, C.; Jacobson, J.; Foley, A.; Partridge, L. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab., 2010, 11(1), 35-46.
79. Lee, C. K.; Klopp, R. G.; Weindruch, R.; Prolla, T. A. Gene expression profile of aging and its retardation by caloric restriction. Science, 1999, 285(5432), 1390-3.
80. Ly, D. H.; Lockhart, D. J.; Lerner, R. A.; Schultz, P. G. Mitotic misregulation and human aging. Science, 2000, 287(5462), 2486-92.
81. Ferrington, D. A.; Husom, A. D.; Thompson, L. V. Altered proteasome structure, function, and oxidation in aged muscle. FASEB J., 2005, 19(6), 644-6.
82. Vernace, V. A.; Arnaud, L.; Schmidt-Glenewinkel, T.; Figueiredo-Pereira, M. E. Aging perturbs 26S proteasome assembly in Drosophila melanogaster. FASEB J., 2007, 21(11), 2672-82.
83. Grune, T.; Jung, T.; Merker, K.; Davies, K.J. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. Int. J. Biochem. Cell Bio. l, 2004, 36(12), 2519-30.
84. Andersson, V.; Hanzen, S.; Liu, B.; Molin, M.; Nystrom, T. Enhancing protein disaggregation restores proteasome activity in aged cells. Aging (Albany NY), 2013, 5(11), 802-812.
85. Bulteau, A.L.; Petropoulos, I.; Friguet, B. Age-related alterations of proteasome structure and function in aging epidermis. Exp. Gerontol., 2000, 35(6-7), 767-77.
86. Carrard, G.; Dieu, M.; Raes, M.; Toussaint, O.; Friguet, B. Impact of ageing on proteasome structure and function in human lymphocytes. Int. J. Biochem. Cell Biol., 2003, 35(5), 728-39.
87. Chondrogianni, N.; Stratford, F. L.; Trougakos, I. P.; Friguet, B.; Rivett, A. J.; Gonos, E. S. Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescencelike phenotype upon its inhibition and resistance to stress upon its activation. J. Biol. Chem., 2003, 278(30), 28026-37.
88. Petropoulos, I.; Conconi, M.; Wang, X.; Hoenel, B.; Bregegere, F.; Milner, Y.; Friguet, B. Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. J. Gerontol. A Biol. Sci. Med. Sci., 2000, 55(5), B220-7.
89. Wagner, B. J.; Margolis, J. W. Age-dependent association of isolated bovine lens multicatalytic proteinase complex (proteasome) with heat-shock protein 90, an endogenous inhibitor. Arch. Biochem. Biophys., 1995, 323(2), 455-62.
90. Bardag-Gorce, F.; Farout, L.; Veyrat-Durebex, C.; Briand, Y.; Briand, M. Changes in 20S proteasome activity during ageing of the LOU rat. Mol. Biol. Rep., 1999, 26(1-2), 89-93.
91. Bulteau, A. L.; Szweda, L. I.; Friguet, B. Age-dependent declines in proteasome activity in the heart. Arch. Biochem. Biophys., 2002, 397(2), 298-304.
92. Conconi, M.; Szweda, L. I.; Levine, R. L.; Stadtman, E. R.; Friguet, B. Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90. Arch. Biochem. Biophys., 1996, 331(2), 232-40.
93. Husom, A. D.; Peters, E. A.; Kolling, E. A.; Fugere, N. A.; Thompson, L. V.; Ferrington, D. A. Altered proteasome function and subunit composition in aged muscle. Arch. Biochem. Biophys., 2004, 421(1), 67-76.
94. Keller, J. N.; Hanni, K. B.; Markesbery, W. R. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech. Ageing Dev., 2000, 113(1), 61-70.
95. Shibatani, T.; Nazir, M.; Ward, W. F. Alteration of rat liver 20S proteasome activities by age and food restriction. J. Gerontol. A Biol. Sci. Med. Sci.,1996, 51(5), B316-22.
96. Torres, C.; Lewis, L.; Cristofalo, V. J. Proteasome inhibitors shorten replicative life span and induce a senescent-like phenotype of human fibroblasts. J. Cell Physiol., 2006, 207(3), 845-53.
97. Tomaru, U.; Takahashi, S.; Ishizu, A.; Miyatake, Y.; Gohda, A.; Suzuki, S.; Ono, A.; Ohara, J.; Baba, T.; Murata, S.; Tanaka, K.; Kasahara, M. Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities. Am. J. Pathol., 2012, 180(3), 963-72.
98. Fredriksson, A.; Johansson Krogh, E.; Hernebring, M.; Pettersson, E.; Javadi, A.; Almstedt, A.; Nystrom, T. Effects of aging and reproduction on protein quality control in soma and gametes of Drosophila melanogaster. Aging Cell, 2012, 11(4), 634-43.
99. Tsakiri, E. N.; Sykiotis, G. P.; Papassideri, I. S.; Gorgoulis, V. G.; Bohmann, D.; Trougakos, I. P. Differential regulation of proteasome functionality in reproductive vs. somatic tissues of Drosophila during aging or oxidative stress. FASEB J., 2013, 27(6), 2407-20
100. Hamer, G.; Matilainen, O.; Holmberg, C.I. A photoconvertible reporter of the ubiquitin-proteasome system in vivo. Nat. Methods, 2010, 7(6), 473-8.
101. Evans, M. J.; Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos. Nature, 1981, 292(5819), 154-6.
102. Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; Waknitz, M.A.; Swiergiel, J.J.; Marshall, V.S.; Jones, J.M. Embryonic stem cell lines derived from human blastocysts. Science, 1998, 282(5391), 1145-7.
103. Assou, S.; Cerecedo, D.; Tondeur, S.; Pantesco, V.; Hovatta, O.; Klein, B.; Hamamah, S.; De Vos, J. A gene expression signature shared by human mature oocytes and embryonic stem cells. BMC Genomics, 2009, 10, 10.
104. Pathare, G.R.; Nagy, I.; Bohn, S.; Unverdorben, P.; Hubert, A.; Korner, R.; Nickell, S.; Lasker, K.; Sali, A.; Tamura, T.; Nishioka, T.; Forster, F.; Baumeister, W.; Bracher, A. The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. Proc. Natl. Acad. Sci. USA, 2012, 109(1), 149-54.
105. Atkinson, S. P.; Collin, J.; Irina, N.; Anyfantis, G.; Kyung, B. K.; Lako, M.; Armstrong, L. A putative role for the immunoproteasome in the maintenance of pluripotency in human embryonic stem cells. Stem Cells, 2012, 30(7), 1373-84.
106. Hernebring, M.; Brolen, G.; Aguilaniu, H.; Semb, H.; Nystrom, T. Elimination of damaged proteins during differentiation of embryonic stem cells. Proc. Natl. Acad. Sci. USA, 2006, 103(20), 7700-5.
107. Hernebring, M.; Fredriksson, A.; Liljevald, M.; Cvijovic, M.; Norrman, K.; Wiseman, J.; Semb, H.; Nystrom, T. Removal of damaged proteins during ES cell fate specification requires the proteasome activator PA28. Sci. Rep., 2013, 3, 1381.
108. Li, L.; Xie, T. Stem cell niche: structure and function. Annu. Rev. Cell Dev. Biol., 2005, 21, 605-31.
109. Signer, R. A.; Morrison, S. J. Pluripotency of spermatogonial stem cells from adult mouse testis. Mechanisms that regulate stem cell aging and life span. Cell Stem Cell, 2013, 12(2), 152-65.
110. Guan, K.; Nayernia, K.; Maier, L. S.; Wagner, S.; Dressel, R.; Lee, J. H.; Nolte, J.; Wolf, F.; Li, M.; Engel, W.; Hasenfuss, G. Nature, 2006, 440(7088), 1199-203.
111. Nicholas, C. R.; Haston, K. M.; Grewall, A. K.; Longacre, T. A.; Reijo Pera, R. A. Transplantation directs oocyte maturation from embryonic stem cells and provides a therapeutic strategy for female infertility. Hum. Mol. Genet., 2009, 18(22), 4376-89.
112. Kirkwood, T. B. Evolution of ageing. Nature, 1977, 270(5635), 301-4.
113. Aguilaniu, H.; Gustafsson, L.; Rigoulet, M.; Nystrom, T. Asymmetric inheritance of oxidatively damaged proteins during cytokinesis. Science, 2003, 299(5613), 1751-3.
114. Erjavec, N.; Cvijovic, M.; Klipp, E.; Nystrom, T. Selective benefits of damage partitioning in unicellular systems and its effects on aging. Proc. Natl. Acad. Sci. USA, 2008,105(48), 18764-9.
115. Erjavec, N.; Nystrom, T. Sir2p-dependent protein segregation gives rise to a superior reactive oxygen species management in the progeny of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA, 2007, 104(26), 10877-81.
116. Cohen, E.; Dillin, A. The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat. Rev. Neurosci., 2008, 9(10), 759-67.
117. Zabel, C.; Nguyen, H.P.; Hin, S.C.; Hartl, D.; Mao, L.; Klose, J. Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders. J. Proteomics, 2010, 73(11), 2230-8.
118. Tonoki, A.; Kuranaga, E.; Tomioka, T.; Hamazaki, J.; Murata, S.; Tanaka, K.; Miura, M. Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process. Mol. Cell Biol., 2009, 29(4), 1095-106.
119. Matsuda, N.; Tanaka, K. Does impairment of the ubiquitinproteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease? J. Alzheimers Dis., 2010, 19(1), 1-9.
120. Keck, S.; Nitsch, R.; Grune, T.; Ullrich, O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem., 2003, 85(1), 115-22.
121. Grune, T.; Botzen, D.; Engels, M.; Voss, P.; Kaiser, B.; Jung, T.; Grimm, S.; Ermak, G.; Davies, K. J. Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch. Biochem. Biophys., 2010, 500(2), 181-8.
122. Dickey, C.A.; Koren, J.; Zhang, Y.J.; Xu, Y.F.; Jinwal, U.K.; Birnbaum, M. J.; Monks, B.; Sun, M.; Cheng, J. Q.; Patterson, C.; Bailey, R. M.; Dunmore, J.; Soresh, S.; Leon, C.; Morgan, D.; Petrucelli, L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. USA, 2008, 105(9), 3622-7.
123. Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; De Lucia, M.; McGowan, E.; Lewis, J.; Prihar, G.; Kim, J.; Dillmann, W. H.; Browne, S. E.; Hall, A.; Voellmy, R.; Tsuboi, Y.; Dawson, T. M.; Wolozin, B.; Hardy, J.; Hutton, M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet., 2004, 13(7), 703-14.
124. Lee, M. J.; Lee, J. H.; Rubinsztein, D. C. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog. Neurobiol., 2013, 105, 49-59.
125. Dange, T.; Smith, D.; Noy, T.; Rommel, P. C.; Jurzitza, L.; Cordero, R. J.; Legendre, A.; Finley, D.; Goldberg, A. L.; Schmidt, M. Blm10 protein promotes proteasomal substrate turnover by an active gating mechanism. J. Biol. Chem., 2011, 286(50), 42830-9.
126. Jinwal, U. K.; Koren, J., 3rd; Borysov, S. I.; Schmid, A. B.; Abisambra, J. F.; Blair, L. J.; Johnson, A. G.; Jones, J. R.; Shults, C. L.; O'Leary, J. C., 3rd; Jin, Y.; Buchner, J.; Cox, M. B.; Dickey, C. A. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J. Neurosci., 2010, 30(2), 591-9.
127. Blair, L. J.; Nordhues, B. A.; Hill, S. E.; Scaglione, K. M.; O'Leary, J. C., 3rd; Fontaine, S. N.; Breydo, L.; Zhang, B.; Li, P.; Wang, L.; Cotman, C.; Paulson, H. L.; Muschol, M.; Uversky, V. N.; Klengel, T.; Binder, E. B.; Kayed, R.; Golde, T. E.; Berchtold, N.; Dickey, C. A. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J. Clin. Invest., 2013, 123(10), 4158-69.
128. Tseng, B. P.; Green, K. N.; Chan, J. L.; Blurton-Jones, M.; LaFerla, F. M. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging, 2008, 29(11), 1607-18.
129. McNaught, K. S.; Perl, D. P.; Brownell, A. L.; Olanow, C. W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol., 2004, 56(1), 149-62.
130. Bedford, L.; Hay, D.; Devoy, A.; Paine, S.; Powe, D. G.; Seth, R.; Gray, T.; Topham, I.; Fone, K.; Rezvani, N.; Mee, M.; Soane, T.; Layfield, R.; Sheppard, P. W.; Ebendal, T.; Usoskin, D.; Lowe, J.; Mayer, R. J. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci.,2008, 28(33), 8189-98.
131. Wahl, C.; Kautzmann, S.; Krebiehl, G.; Strauss, K.; Woitalla, D.; Muller, T.; Bauer, P.; Riess, O.; Kruger, R. A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson's disease patients. J. Neural Transm.,2008, 115(8), 1141-8.
132. Tofaris, G.K.; Layfield, R.; Spillantini, M.G. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett, 2001, 509(1), 22-6.
133. Tashiro, Y.; Urushitani, M.; Inoue, H.; Koike, M.; Uchiyama, Y.; Komatsu, M.; Tanaka, K.; Yamazaki, M.; Abe, M.; Misawa, H.; Sakimura, K.; Ito, H.; Takahashi, R. Motor neuron-specific disrup tion of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. J. Biol. Chem., 2012, 287(51), 42984-94.
134. Gusella, J. F.; MacDonald, M. E.; Ambrose, C. M.; Duyao, M. P. Molecular genetics of Huntington's disease. Arch. Neurol., 1993, 50(11), 1157-63.
135. Vonsattel, J. P.; DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol., 1998, 57(5), 369-84.
136. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 1993, 72(6), 971-83.
137. Sanchez, I.; Mahlke, C.; Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature, 2003, 421(6921), 373-9.
138. Snell, R.G.; MacMillan, J.C.; Cheadle, J.P.; Fenton, I.; Lazarou, L.P.; Davies, P.; MacDonald, M. E.; Gusella, J. F.; Harper, P. S.; Shaw, D. J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet., 1993, 4(4), 393-7.
139. Nance, M. A.; Myers, R. H. Juvenile onset Huntington's disease--clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev., 2001, 7(3), 153-7.
140. Holmberg, C. I.; Staniszewski, K. E.; Mensah, K. N.; Matouschek, A.; Morimoto, R. I. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J., 2004, 23(21), 4307-18.
141. Seo, H.; Sonntag, K. C.; Kim, W.; Cattaneo, E.; Isacson, O. Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLOS One, 2007, 2(2), e238.
142. Hipp, M.S.; Patel, C.N.; Bersuker, K.; Riley, B.E.; Kaiser, S.E.; Shaler, T.A.; Brandeis, M.; Kopito, R. R. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. J. Cell Biol., 2012, 196(5), 573-87.
143. Kalchman, M.A.; Graham, R.K.; Xia, G.; Koide, H.B.; Hodgson, J.G.; Graham, K.C.; Goldberg, Y.P.; Gietz, R.D.; Pickart, C.M.; Hayden, M.R. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem., 1996, 271(32), 19385-94.
144. Finkbeiner, S.; Mitra, S. The ubiquitin-proteasome pathway in Huntington's disease. ScientificWorldJournal, 2008, 8, 421-33.
145. Sieradzan, K. A.; Mechan, A. O.; Jones, L.; Wanker, E. E.; Nukina, N.; Mann, D. M. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol., 1999, 156(1), 92-9.
146. Waelter, S.; Boeddrich, A.; Lurz, R.; Scherzinger, E.; Lueder, G.; Lehrach, H.; Wanker, E. E. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell, 2001, 12(5), 1393-407.
147. Bence, N. F.; Sampat, R. M.; Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 2001, 292(5521), 1552-5.
148. Diaz-Hernandez, M.; Valera, A.G.; Moran, M.A.; Gomez-Ramos, P.; Alvarez-Castelao, B.; Castano, J.G.; Hernandez, F.; Lucas, J.J. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J. Neurochem., 2006, 98(5), 1585-96.
149. Ardley, H.C.; Hung, C.C.; Robinson, P.A. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett., 2005, 579(3), 571-6.
150. Ciechanover, A.; Brundin, P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron, 2003, 40(2), 427-46.
151. Venkatraman, P.; Wetzel, R.; Tanaka, M.; Nukina, N.; Goldberg, A. L. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutaminecontaining proteins. Mol. Cell., 2004, 14(1), 95-104.
152. Bennett, E.J.; Bence, N.F.; Jayakumar, R.; Kopito, R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell., 2005, 17(3), 351-65.
153. Pratt, G.; Rechsteiner, M. Proteasomes cleave at multiple sites within polyglutamine tracts: activation by PA28gamma(K188E). J. Biol. Chem., 2008, 283(19), 12919-25.
154. Finkel, T.; Serrano, M.; Blasco, M.A. The common biology of cancer and ageing. Nature, 2007, 448, (7155)767-74.
155. Arlt, A.; Bauer, I.; Schafmayer, C.; Tepel, J.; Muerkoster, S.S.; Brosch, M.; Roder, C.; Kalthoff, H.; Hampe, J.; Moyer, M.P.; Folsch, U.R.; Schafer, H. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene, 2009, 28(45), 3983-96.
156. Chen, L.; Madura, K. Increased proteasome activity, ubiquitinconjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res., 2005, 65(13), 5599-606.
157. Zhang, W. G.; Yu, J. P.; Wu, Q. M.; Tong, Q.; Li, S. B.; Wang, X. H.; Xie, G.J. Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells. World J. Gastroenterol., 2004, 10(19), 2779-84.
158. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer, 2005, 5(10), 761-72.
159. Ling, Y. H.; Liebes, L.; Ng, B.; Buckley, M.; Elliott, P. J.; Adams, J.; Jiang, J. D.; Muggia, F. M.; Perez-Soler, R. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther., 2002, 1(10), 841-9.
160. Pei, X. Y.; Dai, Y.; Grant, S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia, 2003, 17(10), 2036-45.
161. Teicher, B.A.; Ara, G.; Herbst, R.; Palombella, V. J.; Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res., 1999, 5(9), 2638-45.
162. Frankel, A.; Man, S.; Elliott, P.; Adams, J.; Kerbel, R. S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res., 2000, 6(9), 3719-28.
163. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V.J.; Elliott, P.J.; Adams, J.; Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 2001, 61(7), 3071-6.
164. Delic, J.; Masdehors, P.; Omura, S.; Cosset, J.M.; Dumont, J.; Binet, J.L.; Magdelenat, H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alphainitiated apoptosis. Br. J. Cancer, 1998, 77(7), 1103-7.
165. Orlowski, R.Z.; Eswara, J.R.; Lafond-Walker, A.; Grever, M.R.; Orlowski, M.; Dang, C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res., 1998, 58(19), 4342-8.
166. Soligo, D.; Servida, F.; Delia, D.; Fontanella, E.; Lamorte, G.; Caneva, L.; Fumiatti, R.; Lambertenghi Deliliers, G. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol., 2001, 113(1), 126-35.
167. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004, 5(5), 417-21.
168. Almond, J. B.; Cohen, G. M. The proteasome: a novel target for cancer chemotherapy. Leukemia, 2002, 16(4), 433-43.
169. Chen, W.; Hu, X. T.; Shi, Q. L.; Zhang, F. B.; He, C. Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal Cancer Cell migration, survival and tumorigenicity. Oncol. Rep., 2009, 21(2), 531-7.
170. Goy, A.; Younes, A.; McLaughlin, P.; Pro, B.; Romaguera, J. E.; Hagemeister, F.; Fayad, L.; Dang, N. H.; Samaniego, F.; Wang, M.; Broglio, K.; Samuels, B.; Gilles, F.; Sarris, A. H.; Hart, S.; Trehu, E.; Schenkein, D.; Cabanillas, F.; Rodriguez, A. M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 2005, 23(4), 667-75.
171. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res., 2008, 14(6), 1649-57.
172. Richardson, P. G.; Mitsiades, C.; Schlossman, R.; Ghobrial, I.; Hideshima, T.; Munshi, N.; Anderson, K. C. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev. Anticancer Ther., 2008, 8(7), 1053-72.
173. Nencioni, A.; Grunebach, F.; Patrone, F.; Ballestrero, A.; Brossart, P. Proteasome inhibitors: antitumor effects and beyond. Leukemia, 2007, 21(1), 30-6.
174. Richardson, P. G.; Mitsiades, C.; Hideshima, T.; Anderson, K. C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med., 2006, 57, 33-47.
175. Chen, C. I.; Kouroukis, C. T.; White, D.; Voralia, M.; Stadtmauer, E.; Stewart, A. K.; Wright, J. J.; Powers, J.; Walsh, W.; Eisenhauer, E. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25(12), 1570-5.
176. Treon, S. P.; Hunter, Z. R.; Matous, J.; Joyce, R. M.; Mannion, B.; Advani, R.; Cook, D.; Songer, J.; Hill, J.; Kaden, B. R.; Sharon, D.; Steiss, R.; Leleu, X.; Branagan, A. R.; Badros, A. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin. Cancer Res., 2007, 13(11), 3320-5.
177. Belch, A.; Kouroukis, C. T.; Crump, M.; Sehn, L.; Gascoyne, R. D.; Klasa, R.; Powers, J.; Wright, J.; Eisenhauer, E. A. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann. Oncol., 2007, 18(1), 116-21.
178. Fisher, R.I.; Bernstein, S.H.; Kahl, B.S.; Djulbegovic, B.; Robertson, M.J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J.P.; Lonial, S.; Stadtmauer, E.A.; O'Connor, O.A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol.,2006, 24(30), 4867-74.
179. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T.H.; Neuteboom, S.T.; Richardson, P.; Palladino, M. A.; Anderson, K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8(5), 407-19.
180. Kuhn, D.J.; Chen, Q.; Voorhees, P.M.; Strader, J.S.; Shenk, K.D.; Sun, C.M.; Demo, S.D.; Bennett, M.K.; van Leeuwen, F.W.; Chanan-Khan, A.A.; Orlowski, R.Z. otent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 2007, 110(9), 3281-90.
181. Chondrogianni, N.; Petropoulos, I.; Franceschi, C.; Friguet, B.; Gonos, E. S. Fibroblast cultures from healthy centenarians have an active proteasome. Exp. Gerontol., 2000, 35(6-7), 721-8.
182. Perez, V. I.; Buffenstein, R.; Masamsetti, V.; Leonard, S.; Salmon, A. B.; Mele, J.; Andziak, B.; Yang, T.; Edrey, Y.; Friguet, B.; Ward, W.; Richardson, A.; Chaudhuri, A. Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat. Proc. Natl. Acad. Sci. USA, 2009, 106(9), 3059-64.
183. Ungvari, Z.; Csiszar, A.; Sosnowska, D.; Philipp, E. E.; Campbell, C. M.; McQuary, P. R.; Chow, T. T.; Coelho, M.; Didier, E.S.; Gelino, S.; Holmbeck, M.A.; Kim, I.; Levy, E.; Sonntag, W. E.; Whitby, P. W.; Austad, S. N.; Ridgway, I. Testing predictions of the oxidative stress hypothesis of aging using a novel invertebrate model of longevity: the giant clam (Tridacna derasa). J. Gerontol. A Biol. Sci. Med. Sci., 2013, 68(4), 359-67.
184. Chondrogianni, N.; Tzavelas, C.; Pemberton, A. J.; Nezis, I. P.; Rivett, A. J.; Gonos, E. S. Overexpression of proteasome beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates. J. Biol. Chem., 2005, 280(12), 11840-50.
185. Chondrogianni, N.; Gonos, E. S. Overexpression of hUMP1/POMP proteasome accessory protein enhances proteasome-mediated antioxidant defence. Exp. Gerontol., 2007, 42(9), 899-903.
186. Chen, Q.; Thorpe, J.; Dohmen, J. R.; Li, F.; Keller, J. N. Ump1 extends yeast lifespan and enhances viability during oxidative stress: central role for the proteasome? Free Radic. Biol. Med., 2006, 40(1), 120-6.
187. Dohmen, R. J.; Willers, I.; Marques, A. J. Biting the hand that feeds: Rpn4-dependent feedback regulation of proteasome function. Biochim. Biophys. Acta, 2007, 1773(11), 1599-604.
188. Wang, L.; Mao, X.; Ju, D.; Xie, Y. Rpn4 is a physiological substrate of the Ubr2 ubiquitin ligase. J. Biol. Chem., 2004, 279(53), 55218-23.
189. Ma, M.; Liu, Z. L. Comparative transcriptome profiling analyses during the lag phase uncover YAP1, PDR1, PDR3, RPN4, and HSF1 as key regulatory genes in genomic adaptation to the lignocellulose derived inhibitor HMF for Saccharomyces cerevisiae. BMC Genomics, 2010, 11, 660.
190. Morimoto, R. I. The heat shock response: systems biology of proteotoxic stress in aging and disease. Cold Spring Harb. Symp. Quant. Biol., 2011, 76, 91-9.
191. Kruegel, U.; Robison, B.; Dange, T.; Kahlert, G.; Delaney, J. R.; Kotireddy, S.; Tsuchiya, M.; Tsuchiyama, S.; Murakami, C. J.; Schleit, J.; Sutphin, G.; Carr, D.; Tar, K.; Dittmar, G.; Kaeberlein, M.; Kennedy, B. K.; Schmidt, M. Elevated proteasome capacity extends replicative lifespan in Saccharomyces cerevisiae. PLoS Genet., 2011, 7(9), e1002253.
192. Wolff, S.; Dillin, A. The trifecta of aging in Caenorhabditis elegans. Exp. Gerontol., 2006, 41(10), 894-903.
193. Fontana, L.; Partridge, L.; Longo, V. D. Extending healthy life span--from yeast to humans. Science,2010, 328(5976), 321-6.
194. Mair, W.; Dillin, A. Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem., 2008, 77, 727-54.
195. Wullschleger, S.; Loewith, R.; Hall, M. N. TOR signaling in growth and metabolism. Cell, 2006, 124(3), 471-84.
196. Zid, B. M.; Rogers, A. N.; Katewa, S. D.; Vargas, M. A.; Kolipinski, M. C.; Lu, T. A.; Benzer, S.; Kapahi, P. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell, 2009, 139(1), 149-60.
197. Carrano, A.C.; Liu, Z.; Dillin, A.; Hunter, T. A conserved ubiquitination pathway determines longevity in response to diet restriction. Nature, 2009, 460(7253), 396-9.
198. Bishop, N. A.; Guarente, L. Two neurons mediate diet-restrictioninduced longevity in C. elegans. Nature, 2007, 447(7144), 545-9.
199. Ferguson, A.A.; Springer, M.G.; Fisher, A. L. skn-1-Dependent and-independent regulation of aip-1 expression following metabolic stress in Caenorhabditis elegans. Mol. Cell Biol., 2010, 30(11), 2651-67.
200. Stanhill, A.; Haynes, C.M.; Zhang, Y.; Min, G.; Steele, M.C.; Kalinina, J.; Martinez, E.; Pickart, C. M.; Kong, X. P.; Ron, D. An arsenite-inducible 19S regulatory particle-associated protein adapts proteasomes to proteotoxicity. Mol. Cell., 2006, 23(6), 875-85.
201. Hassan, W.M.; Merin, D.A.; Fonte, V.; Link, C.D. AIP-1 ameliorates beta-amyloid peptide toxicity in a Caenorhabditis elegans Alzheimer's disease model. Hum. Mol. Genet., 2009, 18(15), 2739-47.
202. Yun, C.; Stanhill, A.; Yang, Y.; Zhang, Y.; Haynes, C. M.; Xu, C. F.; Neubert, T. A.; Mor, A.; Philips, M. R.; Ron, D. Proteasomal adaptation to environmental stress links resistance to proteotoxicity with longevity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 2008, 105(19), 7094-9.
203. Kahn, N. W.; Rea, S. L.; Moyle, S.; Kell, A.; Johnson, T. E. Proteasomal dysfunction activates the transcription factor SKN-1 and produces a selective oxidative-stress response in Caenorhabditis elegans. Biochem. J., 2008, 409(1), 205-13.
204. Kapeta, S.; Chondrogianni, N.; Gonos, E. S. Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. J. Biol. Chem., 2010, 285(11), 8171-84.
205. Kraft, D. C.; Deocaris, C. C.; Wadhwa, R.; Rattan, S. I. Preincubation with the proteasome inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in aging human skin fibroblasts. Ann. N. Y. Acad. Sci., 2006, 1067, 420-4.
206. Kwak, M. K.; Wakabayashi, N.; Greenlaw, J. L.; Yamamoto, M.; Kensler, T. W. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell Biol., 2003, 23(23), 8786-94.
207. Li, X.; Matilainen, O.; Jin, C.; Glover-Cutter, K. M.; Holmberg, C. I.; Blackwell, T. K. Specific SKN-1/Nrf stress responses to perturbations in translation elongation and proteasome activity. PLoS Genet., 2011, 7(6), e1002119.
208. Pickering, A. M.; Linder, R. A.; Zhang, H.; Forman, H. J.; Davies, K. J. Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress. J. Biol. Chem., 2012, 287(13), 10021-31.
209. Pickering, A. M.; Staab, T. A.; Tower, J.; Sieburth, D.; Davies, K. J. A conserved role for the 20S proteasome and Nrf2 transcription factor in oxidative stress adaptation in mammals, Caenorhabditis elegans and Drosophila melanogaster. J. Exp. Biol., 2013, 216(4), 543-53.
210. Radhakrishnan, S. K.; Lee, C. S.; Young, P.; Beskow, A.; Chan, J. Y.; Deshaies, R. J. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol. Cell., 2010, 38(1), 17-28.
211. Bartke, A. Insulin and aging. Cell Cycle, 2008, 7(21), 3338-43.
212. Holzenberger, M.; Dupont, J.; Ducos, B.; Leneuve, P.; Geloen, A.; Even, P. C.; Cervera, P.; Le Bouc, Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature, 2003, 421(6919), 182-7.
213. Panowski, S. H.; Dillin, A. Signals of youth: endocrine regulation of aging in Caenorhabditis elegans. Trends Endocrinol. Metab., 2009, 20(6), 259-64.
214. Tatar, M.; Bartke, A.; Antebi, A. The endocrine regulation of aging by insulin-like signals. Science, 2003, 299(5611), 1346-51.
215. Flachsbart, F.; Caliebe, A.; Kleindorp, R.; Blanche, H.; von Eller-Eberstein, H.; Nikolaus, S.; Schreiber, S.; Nebel, A. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc. Natl. Acad. Sci. USA, 2009, 106(8), 2700-5.
216. Suh, Y.; Atzmon, G.; Cho, M. O.; Hwang, D.; Liu, B.; Leahy, D. J.; Barzilai, N.; Cohen, P. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc. Natl. Acad. Sci. USA, 2008, 105(9), 3438-42.
217. Willcox, B. J.; Donlon, T. A.; He, Q.; Chen, R.; Grove, J. S.; Yano, K.; Masaki, K. H.; Willcox, D. C.; Rodriguez, B.; Curb, J. D. FOXO3A genotype is strongly associated with human longevity. Proc. Natl. Acad. Sci. USA, 2008, 105(37), 13987-92.
218. Bluher, M.; Kahn, B. B.; Kahn, C. R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science,2003, 299(5606), 572-4.
219. Kenyon, C. The plasticity of aging: insights from long-lived mutants. Cell, 2005, 120(4), 449-60.
220. Kenyon, C.; Chang, J.; Gensch, E.; Rudner, A.; Tabtiang, R. A C. elegans mutant that lives twice as long as wild type. Nature, 1993, 366(6454), 461-4.
221. Panowski, S. H.; Wolff, S.; Aguilaniu, H.; Durieux, J.; Dillin, A. PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature, 2007, 447(7144), 550-5.
222. Tatar, M.; Kopelman, A.; Epstein, D.; Tu, M.P.; Yin, C.M.; Garofalo, R.S. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science, 2001, 292(5514), 107-10.
223. Ghazi, A.; Henis-Korenblit, S.; Kenyon, C. Regulation of Caenorhabditis elegans lifespan by a proteasomal E3 ligase complex. Proc. Natl. Acad. Sci. USA, 2007, 104(14), 5947-52.
224. Matilainen, O.; Arpalahti, L.; Rantanen, V.; Hautaniemi, S.; Holmberg, C. I. Insulin/IGF-1 signaling regulates proteasome activity through the deubiquitinating enzyme UBH-4. Cell Rep., 2013, 3(6), 1980-95.
225. Morley, J. F.; Brignull, H. R.; Weyers, J. J.; Morimoto, R. I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10417-22.
226. Kerr, F.; Augustin, H.; Piper, M.D.; Gandy, C.; Allen, M.J.; Lovestone, S.; Partridge, L. Dietary restriction delays aging, but not neuronal dysfunction, in Drosophila models of Alzheimer's disease. Neurobiol. Aging, 2011, 32(11), 1977-89.
227. Link, C. D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 1995, 92(20), 9368-72.
228. Florez-McClure, M. L.; Hohsfield, L.A.; Fonte, G.; Bealor, M.T.; Link, C.D. Decreased insulin-receptor signaling promotes the autophagic degradation of beta-amyloid peptide in C. elegans. Autophagy, 2007, 3(6), 569-80.
229. Bartke, A. Growth hormone, insulin and aging: the benefits of endocrine defects. Exp. Gerontol., 2011, 46(2-3), 108-11.
230. Iwasa, H.; Yu, S.; Xue, J.; Driscoll, M. Novel EGF pathway regulators modulate C. elegans healthspan and lifespan via EGF receptor, PLC-gamma, and IP3R activation. Aging Cell, 2010, 9(4), 490-505.
231. Liu, G.; Rogers, J.; Murphy, C. T.; Rongo, C. EGF signalling activates the ubiquitin proteasome system to modulate C. elegans lifespan. EMBO J., 2011, 30(15), 2990-3003.
232. Partridge, L.; Gems, D.; Withers, D. J. Sex and death: what is the connection? Cell, 2005, 120(4), 461-72.
233. Flatt, T.; Min, K. J.; D'Alterio, C.; Villa-Cuesta, E.; Cumbers, J.; Lehmann, R.; Jones, D. L.; Tatar, M. Drosophila germ-line modulation of insulin signaling and lifespan. Proc. Natl. Acad. Sci. USA, 2008, 105(17), 6368-73.
234. Kenyon, C. A pathway that links reproductive status to lifespan in Caenorhabditis elegans. Ann. N. Y. Acad. Sci.,2010, 1204, 156-62.
235. Shemesh, N.; Shai, N.; Ben-Zvi, A. Germline stem cell arrest inhibits the collapse of somatic proteostasis early in Caenorhabditis elegans adulthood. Aging Cell, 2013, 12(5), 814-22.
236. Vilchez, D.; Boyer, L.; Lutz, M.; Merkwirth, C.; Morantte, I.; Tse, C.; Spencer, B.; Page, L.; Masliah, E.; Berggren, W.T.; Gage, F.H.; Dillin, A. FOXO4 is necessary for neural differentiation of human embryonic stem cells. Aging Cell, 2013, 12(3), 518-22.
237. Ermolaeva, M.A.; Segref, A.; Dakhovnik, A.; Ou, H.L.; Schneider, J.I.; Utermohlen, O.; Hoppe, T.; Schumacher, B. DNA damage in germ cells induces an innate immune response that triggers systemic stress resistance. Nature, 2013, 501(7467), 416-20.
238. Copeland, J.M.; Cho, J.; Lo, T. Jr.; Hur, J.H.; Bahadorani, S.; Arabyan, T.; Rabie, J.; Soh, J.; Walker, D.W. Extension of Drosophila life span by RNAi of the mitochondrial respiratory chain. Curr. Biol., 2009, 19(19), 1591-8.
239. Dillin, A.; Hsu, A. L.; Arantes-Oliveira, N.; Lehrer-Graiwer, J.; Hsin, H.; Fraser, A. G.; Kamath, R. S.; Ahringer, J.; Kenyon, C. Rates of behavior and aging specified by mitochondrial function during development. Science, 2002, 298(5602), 2398-401.
240. Feng, J.; Bussiere, F.; Hekimi, S. Mitochondrial electron transport is a key determinant of life span in Caenorhabditis elegans. Dev. Cell, 2001, 1(5), 633-44.
241. Houtkooper, R. H.; Mouchiroud, L.; Ryu, D.; Moullan, N.; Katsyuba, E.; Knott, G.; Williams, R. W.; Auwerx, J. Mitonuclear protein imbalance as a conserved longevity mechanism. Nature, 2013, 497(7450), 451-7.
242. Liu, X.; Jiang, N.; Hughes, B.; Bigras, E.; Shoubridge, E.; Hekimi, S. Evolutionary conservation of the clk-1-dependent mechanism of longevity: loss of mclk1 increases cellular fitness and lifespan in mice. Genes Dev., 2005, 19(20), 2424-34.
243. Vilchez, D.; Simic, M. S.; Dillin, A. Proteostasis and aging of stem cells. Trends Cell. Biol.,2013, 10.1016/j. tcb.2013.09.002.